Kala Pharmaceuticals Inc (KALA) Expected to Post Earnings of -$0.37 Per Share
Brokerages predict that Kala Pharmaceuticals Inc (NASDAQ:KALA) will post ($0.37) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Kala Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.43). The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 20th.
On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($2.22) per share for the current financial year, with EPS estimates ranging from ($2.72) to ($1.95). For the next year, analysts forecast that the company will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.19) to ($1.70). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Kala Pharmaceuticals.
A number of analysts have recently commented on the stock. BidaskClub cut shares of Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. set a $35.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 19th. Wedbush reiterated a “buy” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research note on Thursday, November 30th. Finally, Wells Fargo reiterated an “outperform” rating and issued a $19.00 price target (down previously from $24.00) on shares of Kala Pharmaceuticals in a research note on Thursday, January 25th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Kala Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $35.80.
A number of large investors have recently modified their holdings of KALA. Bank of New York Mellon Corp purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $540,000. Commonwealth Equity Services Inc purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $360,000. EAM Investors LLC purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $1,353,000. American International Group Inc. purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $122,000. Finally, Teachers Retirement System of The State of Kentucky purchased a new position in Kala Pharmaceuticals in the 3rd quarter worth about $105,000. 72.45% of the stock is owned by institutional investors and hedge funds.
Shares of Kala Pharmaceuticals (KALA) traded up $1.30 during mid-day trading on Friday, hitting $18.10. 926,840 shares of the stock were exchanged, compared to its average volume of 214,456. Kala Pharmaceuticals has a 1 year low of $11.81 and a 1 year high of $26.75. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.